- 专利标题： Glucuronide prodrugs of tofacitinib
-
申请号： US15914189申请日： 2018-03-07
-
公开(公告)号： US10472366B2公开(公告)日： 2019-11-12
- 发明人: Daniel D. Long , Donna A.A. Wilton , Mandy M. Loo
- 申请人： THERAVANCE BIOPHARMA R&D IP, LLC
- 申请人地址： US CA South San Francisco
- 专利权人： THERAVANCE BIOPHARMA R&D IP, LLC
- 当前专利权人： THERAVANCE BIOPHARMA R&D IP, LLC
- 当前专利权人地址： US CA South San Francisco
- 代理商 Jeffrey A. Hagenah; Florence Jovic
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61P1/02 ; C07H13/12 ; C07H15/26 ; C07H17/02 ; A61P1/00 ; A61P29/00
摘要：
The invention relates to glucuronide prodrug compounds of the Janus kinase (JAK) inhibitor tofacitinib having formula I: where A1 and R1 are as defined. The invention also relates to pharmaceutical compositions comprising such compounds; methods of using such compounds to treat gastrointestinal inflammatory diseases; and processes and intermediates for preparing such compounds.
公开/授权文献
- US20180258094A1 GLUCURONIDE PRODRUGS OF TOFACITINIB 公开/授权日：2018-09-13
信息查询
